From: Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort
Variables | Outcomes | Crude OR | Pμ | Adjusted ORα | Pμ | |
---|---|---|---|---|---|---|
(95% CI) | (95%CI) | |||||
Birth outcome | MC/SB | Live birth | ||||
n (%) | n (%) | |||||
AL exposure | ||||||
Yes | 13 (12.3) | 159 (9.5) | 1.3 (0.7 – 2.4) | 0.348 | 1.4 (0.8 – 2.5) | 0.295 |
No | 93 (87.7) | 1518 (90.5) | ||||
Quinine exposure | ||||||
Yes | 10 (9.4) | 68 (4.1) | 2.5 (1.2 – 4.9) | 0.011 | 2.5 (1.3 – 5.1) | 0.009 |
No | 96 (90.6) | 1609 (95.9) | ||||
SP exposure | ||||||
Yes | 2 (1.9) | 64 (3.8) | 0.5 (0.1 – 2.0) | 0.318 | 0.5 (0.1 – 2.0) | 0.312 |
No | 104 (98.1) | 1613 (96.2) | ||||
Amodiaquine exposure | ||||||
Yes | 0 (0.0) | 11 (0.7) | - (0) | - | - (0) | - |
No | 106 (100) | 1666 (99.3) | ||||
No anti-malarial exposure | ||||||
Yes | 83 (78.3) | 1380 (82.3) | 0.8 (0.5 – 1.3) | 0.301 | 0.8 (0.5 – 1.2) | 0.260 |
No | 23 (21.7) | 297 (17.7) | ||||
Birth weight (grams) | < 2500 | ≥ 2500 | ||||
n (%) | n (%) | |||||
AL exposure | ||||||
Yes | 9 (11.1) | 150 (9.4) | 1.2 (0.6 – 2.5) | 0.608 | 1.2 (0.6 – 2.5) | 0.573 |
No | 72 (88.9) | 1446 (90.6) | ||||
Quinine exposure | ||||||
Yes | 2 (2.5) | 66 (4.1) | 0.6 (0.1 – 2.4) | 0.463 | 0.6 (0.1 – 2.4) | 0.461 |
No | 79 (97.5) | 1530 (95.9) | ||||
SP exposure | ||||||
Yes | 2 (2.5) | 62 (3.9) | 0.6 (0.2 – 2.6) | 0.520 | 0.7 (0.2 – 3.0) | 0.639 |
No | 79 (97.5) | 1534 (96.1) | ||||
Amodiaquine exposure | ||||||
Yes | 0 (0.0) | 11 (0.7) | - (0) | - | - (0) | - |
No | 100 (100) | 1585 (99.3) | ||||
No anti-malarial exposure | ||||||
Yes | 69 (85.2) | 1311 (82.1) | 1.3 (0.7 – 2.3) | 0.485 | 1.2 (0.6 – 2.3) | 0.564 |
No | 12 (14.8) | 285 (17.9) | ||||
Maturity status at birth | Preterm | Term | ||||
n (%) | n (%) | |||||
AL exposure | ||||||
Yes | 10 (8.9) | 149 (9.5) | 0.9 (0.5 – 1.8) | 0.812 | 0.9 (0.5 – 1.8) | 0.865 |
No | 103 (91.1) | 1415 (90.5) | ||||
Quinine exposure | ||||||
Yes | 10 (8.9) | 58 (3.7) | 2.5 (1.3 – 5.1) | 0.010 | 2.6 (1.3 – 5.3) | 0.007 |
No | 103 (91.1) | 1506 (96.3) | ||||
SP exposure | ||||||
Yes | 7 (6.2) | 57 (3.6) | 1.7 (0.8 – 3.9) | 0.177 | 1.8 (0.8 – 4.1) | 0.160 |
No | 106 (93.8) | 1507 (96.4) | ||||
Amodiaquine exposure | ||||||
Yes | 0 (0.0) | 11 (0.7) | - (0) | - | - (0) | - |
No | 113 (100) | 1553 (99.3) | ||||
No anti-malarial exposure | ||||||
Yes | 88 (77.9) | 1292 (82.6) | 0.7 (0.5 – 1.2) | 0.205 | 0.7 (0.5 – 1.1) | 0.168 |
No | 25 (22.1) | 272 (17.4) |